| MI | Myocardial infarction |
| TCM | Traditional Chinese medicine |
| CVDs | Cardiovascular diseases |
| AMI | Acute myocardial ischemia |
| T2DM-AMI | Type II diabetes with acute myocardial ischemia |
| OS | Oxidative stress |
| PI3K | Phosphatidyl inositol 3-kinase |
| AKT | Threonine protein kinase B |
| TCMSP | Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform |
| OB | Oral bioavailability |
| DL | Drug-likeness |
| PPI | Protein–protein interaction |
| BC | Betweenness centrality |
| CC | Closeness centrality |
| DC | Degree centrality |
| EC | Eigenvector centrality |
| LAC | Local average connectivity |
| NC | Network centrality |
| BP | Biological processes |
| CC | Cell components |
| MF | Molecular function |
| AGE-RAGE | Advanced glycation end-RAGE |
| IL-17 | Interleukin (IL)-17 |
| TNF | Tumor necrosis factor |
| HIF-1 | Hypoxia-inducible factor 1 |
| Jak | Janus kinases |
| mTOR | Mammalian/mechanistic target of rapamycin |
| MYC | c-Myc |
| TP53 | Wild-type (WT) human p53 |
| MAK1 | Mitogen-activated protein kinase 1 |
| MAK3 | Mitogen-activated protein kinase 3 |
| ESR1 | Estrogen receptor 1 |
| RELA | NFkappaB-p65 |
| NF-κB | NF-kappaB |
| VEGF | Vascular endothelial-derived growth factor |